Find an expert

I received education in English literature, applied linguistics and TESOL (Teaching English to Speakers of Other Languages). I consider TESOL my home. My research straddles global language testing, language in education policy, and diversity of Englishes. I have pursued my research within the Asia Pacific region, with a particular focus on developing societies. In examining the role of English, other languages and English language testing for individual mobility and societal development, I have foregrounded inequity, inequality and exclusion. I use qualitative, quantitative and textual data. My work is underpinned by critical perspectives, my multidisciplinary backgrounds and my life experiences as a confused transnational.

Dr Garry Hamilton is a Doctor of Laws, a Fellow of the Institute of Chartered Accountants, a Fellow of the Certified Practising Accountants, a Fellow of the Governance Institute of Australia and a Fellow of the Australian Restructuring Insolvency & Turnaround Association. Until recently, Garry, who is also a chartered accountant, was the only practising solicitor in Australia registered as a liquidator by the Australian Securities and Investments Commission.

Dr Hamilton practises in commercial litigation, corporate reconstruction, debt restructuring and insolvency and has been involved in most of the larger corporate reconstructions and insolvencies in Australia in the past 30 years. He was a Partner with Minter Ellison Lawyers for 25 years and now consults to Taylor David Lawyers, a boutique corporate restructuring and insolvency firm in Brisbane.

Dr Hamilton has advised the Hong Kong, Fijian and Singapore Governments in their review (and in respect of Fiji, its drafting) of their corporate reconstruction legislation, and sat on an advisory board to the Commonwealth Government when the amendments were being made to the insolvency and reconstruction sections of the Corporations Act. In 2018, he also drafted amendments for the Commonwealth Government in its 10-year revision of the Corporations (Aboriginal and Torres Strait Islander) Act. In 2021, Dr Hamilton prepared and submitted to Treasury draft legislation to remedy the ongoing problems with the external administration of corporate trading trusts. He holds degrees in Commerce, Economics and Law from the University of Queensland, a Master of Laws from that university, and a Doctorate (Juridical Science) from the Queensland University of Technology.

Dr Hamilton was a member of the Law Council of Australia’s Corporate Insolvency and Reconstruction Committee from 1993 to 2016, and has been a member of the editorial board of the Insolvency Law Bulletin since 2013.

Publications and conference papers

Books and Book Chapters:

• The Australian Chapter of Collier International Business Insolvency Guide (Author, revised 2021);
• The Australian Chapter of Restructuring and Insolvency Guide (Thomson Reuters, Practical Law, Co-author with Scott Taylor, revised 2021);
• The Companies section of LexisNexis Court Forms and Precedents in Queensland (Author, currently being revised, 2022);
• Invalidations of Securities Upon Insolvency, The Federation Press, 2000 (Author)

Journal articles (most recently published) and conference papers:

• Back to basics – section 588FA, Corporations Act: is a diminution of a company’s assets a pre-condition to the existence of a preference? The mischief of the “doctrine of ultimate effect” exposed (2021) 29 Insolv LJ 14
• Conflicting intermediate appellate court decisions: voidable preferences, third- party payments and the relevance of double-entry book-keeping (2020) 20 Insolvency Law Bulletin 207, (referred to with approval by Rees J in Western Port Holdings Pty Ltd (receivers and managers appointed) (in liq) [2021] NSWSC 232 at [8]) (12 March 2021)
• Vesting of Trust Property in a Bankruptcy Trustee and “reasonable grounds” for Lodging a Caveat: Some helpful Guidance from the High Court (2020) 28 Insolv LJ at 41
• Winding up and Employee Entitlements: Does Corporations Act s 561 give a Liquidator priority over Employee Entitlements for Liquidation Costs and Expenses? (2019) 27 Insolv LJ 81
• Amerind – the Aftermath: Questions and Practical Difficulties Remaining (2019) 27 (3) Insolv LJ 185 at 187
• Preferences and running accounts: “Peak indebtedness”: The Elephant in the room (2018) 26 Insolv LJ 2 at 8
• Battening down the Hatches under the Insolvency Law Reform Act: How to Resist a Request for Documents from Mr Snoopy Creditor: Part 1, Proctor, Feb 2018, Vol 38 No1 at 28
• The case of the mysteriously disappearing secured debt under a deed of company arrangement: hard cases making bad law again? Insolvency Law Bulletin, 2017, Vol 8, No 6 at 116 (republished in Australian Banking and Finance Law Bulletin, Vol 33, No 6, July 2017)
• Winding up insolvent corporate trustees – what happened to the liquidator? Insolvency Law Bulletin, 2016. Vol 17, No 6
• Equitable subrogation of banks and other secured creditors for the recovery of statutory employee entitlements: A "new class of case" or simply a different perspective? (2016) 34 C&SLJ 121

Associate Professor Emma Hamilton-Williams’ career focuses on understanding how immune tolerance is disrupted leading to the development of the autoimmune disease type 1 diabetes. She received her PhD from the Australian National University in 2001, followed by postdoctoral training in Germany and the Scripps Research Institute in the USA.

In 2012, she started a laboratory at the Frazer Institute, University of Queensland where she investigates the gut microbiota as a potential trigger or therapy target for type 1 diabetes, as well as developing an immunotherapy for type 1 diabetes. The overall aim of her research is to find new ways to prevent or treat the underlying immune dysfunction causing autoimmunity.

She is Chief Scientific Officer for an Australia-wide pregnancy-birth cohort study of children at increased risk of type 1 diabetes, which aims to uncover the environmental drivers of this disease. Her laboratory uses big-data approaches including proteomics, metabolomics and metagenomics to understand the function of the gut microbiota linked to disease.

She recently conducted a clinical trial of a microbiome-targeting biotherapy aimed at restoring a healthy microbiome and immune tolerance, with an ultimate aim of preventing type 1 diabetes.

I am a Research Fellow and Leader in Pain Relief Innovation at AIBN, UQ. My research interests sit at the interface of drug delivery and the pain field. My overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management. I am looking for highly motivated postgraduate students.

I also enjoy volunteering within the academic community, most notably as Head of the SBMS ECR Committee and Treasurer for The Queensland Chinese Association of Scientists and Engineers (QCASE). I am currently serving as guest editor of Pain Research and Management.and JoVE Methods Collection.

Research Interests

My research is focusing on nano-based drug formulation and development to improve chronic pain management. I have a broad and unique background in both pharmacology and drug delivery systems, with specific expertise in the development of novel drug products and testing their analgesic efficacy and safety including pharmacokinetic and pharmacodynamic studies. To date, I have established five different techniques to produce painkiller–loaded nanoparticles and nanofibers aimed at improving pain relief for patients where currently available pain-killers either lack efficacy or produce dose-limiting side-effects. For example, there is a small and very potent peptide that has been on the market as a chemical for over 10 years but which cannot be used as a therapeutic due to its short half-life and poor oral bioavailability. In the form of my nanoparticles, that peptide has the potential to become an oral treatment for improving pain management in patients whose pain is currently poorly alleviated by clinically used pain-killers. I have significant expertise in the use of rodent pain models to assess novel analgesics, and I have received excellent training in conducting research in accordance with the stringent requirements of the Quality Management System (quality accreditations (GLP and ISO17025) from NATA). Together, my knowledge, skills and experience will facilitate the efficient translation of my research from the bench to the clinic.

The current focus of the lab is on the development of drug-products to solve one of the largest unmet medical needs in the pain field through use of sustainable materials. 1) We are developing multifunctional sutures including biodegradable pain relief sutures. 2) We are developing my innovative novel nanoparticles, which deliver innate-immune targeting peptides for the treatment of cancer and cancer-related pain. We are establishing a platform for the development of safe, effective delivery for other small molecule peptide drugs in general to pave their way to clinical trials. 3) Our research also investigates the role of C5a and C3a, estrogen, etc. in the pathogenesis of chronic pain including neuropathic pain, cancer-related pain, low back pain and OA pain.

We work in collaboration with other leading Australian and international researchers to stay at the forefront of the drug delivery systems field and the pain field. We also provide preclinical evaluation of novel compounds and formulations.

I undertake multi-disciplinary collaborative research developing mathematical, computational and visualisation approaches and techniques that facilitate the research and education in animal and plant systems.

My major research theme is development of mathematical, computer graphics and simulation approaches and techniques that facilitate the study of genetics, physiology, morphogenesis and ecology at the scale of cells, individual plants and insects and their components. These developments in computational biology are being used to increase our understanding of the dynamics of morphogenesis, and as a tool in applied research and education.

Dr. Jonathan Hand specializes in infectious diseases at Ochsner Health. He earned his medical degree from Louisiana State University School of Medicine, New Orleans and completed his internship, residency and infectious diseases fellowship at the Icahn School of Medicine at Mount Sinai in New York. He is currently an associate professor of medicine at The University of Queensland School of Medicine Ochsner Clinical School. Dr. Hand specializes in the treatment of infections in immunocompromised patients who anticipate or undergo solid organ or hematopoietic stem cell transplantation as well as patients treated with other immunosuppressive therapies. He is a Fellow of the American Society of Transplantation and has served on the executive committee of the Infectious Diseases community of practice. He is also a member of The Transplantation Society, International Society for Heart and Lung Transplantation and Fellow of The Infectious Diseases Society of America. Dr. Hand is the Section Head of Transplant Infectious Diseases and the Medical Director of the Antimicrobial Stewardship Program at Ochsner Medical Center. He also serves as co-chair of the Louisiana Organ Procurement Agency's Advisory Board and Associate Medical Director providing guidance on infectious diseases-related concerns in organ donors and recipients. Dr. Hand leads clinical trials as Associate Research Medical Director of Infectious Diseases for Ochsner Health. His practice and research interests include infectious complications of transplant donors and recipients, vaccine and antimicrobial clinical trials and antimicrobial stewardship.

Dr Amy Hanna’s research expertise includes functional characterization of skeletal and cardiac muscle, and investigation of the mechanisms underlying muscle function in health and disease. Amy is a Research Fellow in the laboratory of Assoc Prof Nathan Palpant at the University of Queensland's Institute for Molecular Bioscience. Amy obtained her PhD in 2014 at the John Curtin School of Medical Research under the supervision of Assoc Prof Nicole Beard and Professor Angela Dulhunty, investigating mechanisms of anthracycline-mediated cardiotoxicity using a combination of electrophysiology and calcium imaging in isolated cardiomyocytes. In 2014 Amy was awarded the Frank Fenner medal for most outstanding PhD thesis at JCSMR. Following completion of her PhD, Amy relocated to the United States to complete postdoctoral studies with Professor Susan Hamilton at Baylor College of Medicine. At BCM, Amy developed a strong interest in muscle diseases linked to calcium mishandling and protein quality control, including congenital myopathy and dilated cardiomyopathy. Amy has been an invited speaker at national and international conferences, and was co-chair of the 2019 Gordon Research Seminar of Muscle EC Coupling. Amy is currently funded by the Muscular Dystrophy Association and the Australian Functional Genomics Network.

Scott Hanna is Principal / Senior Environmental Advisor of Roberschan Environmental based out of Brisbane, Australia, a role he assumed after retiring from a 34 year career with Hatch Ltd. Until his retirement from Hatch, Scott was Director Australia-Asia, and before this, Director North America, for Hatch's Environmental Services Group. As a senior environmental advisor, Scott has been responsible for providing strategic direction and management on projects requiring environmental and social impact assessments; environmental permits, approvals and licenses; sustainable design in development; community stakeholder and indigenous peoples consultation; and climate-change strategies.

Scott is a Senior Environmental Specialist with over 40 years experience in environmental and socioeconomic due diligence assessment, environmental and social impact assessment, natural resource and environmental management, regulatory management, strategic planning, and environmental auditing and training, in the transportation, energy and mining sectors. He has provided senior level environmental advisory services to various levels of government, as well as to the World Bank, Asian Development Bank, and European Bank for Reconstruction and Development, and environmental and regulatory management advice to private sector developers.

Scott has completed environmental assignments in Albania, Australia, Azerbaijan, Bosnia Herzegovina, Canada, China, Estonia, Ghana, Indonesia, Kyrgyzstan, Laos PDR, Nepal, Pakistan, Russia, Samoa, Solomon Islands and Zambia. He is a qualified ISO9001 and ISO14001 Lead Auditor, former Chair of the Transportation Association of Canada's (TAC) Environment Council, former member of TAC's Education and Human Resources Development Council, and a former Adjunct Professor in Simon Fraser University's School of Resource and Environmental Management.

He has a bachelor of science degree in biology (ecology) from the University of Victoria (Canada), and a master of natural resource and environmental management degree from Simon Fraser University (Canada). He is also a Registered Professional Biologist (British Columbia), Professional Biologist (Alberta), certified Environmental Professional (Canada), member of the Environment Institute of Australia and New Zealand and a Certified Environmental Practitioner (Impact Assessment Specialist).

Scott joins the University of Queensland as an Adjunct Professor in joint collaboration with the School of Earth and Environmental Sciences, and the School of Business.

Adam is a public policy scholar and teacher, an expert in health policy and recent recipient of an Australian Research Council Discovery Early Career Researcher Award (DECRA). He is also the Program Director of the Master of Governance and Public Policy, one of Australia's leading postgraduate qualifications for public servants and policy practitioners.

His research primarily concerns how governments draw on ideas and knowledge and negotiate capacity constraints in the policy process. His recent research has addressed policy responses to health crisis, such vaccine hesitancy and anti-microbial resistance, and the role of ignorance and non-knowledge in generating policy failure, such as regarding the Robodebt scandal. He has published in a range of high-ranking international journals, such as Nature, Public Administration, Policy Sciences and Policy and Society.

Adam's DECRA project is entitled Health workforce crisis: understanding political capacity for policy change, and addresses the political factors that constrain and enable health workforce policymaking in Australia, Canada, England and New Zealand.

Adam is available for PhD supervision and is keen to work with students who are interested in the following topics:

• Major issues in health policy, such as workforce shortages, access issues, vaccine hesitancy.
• The politics of health policymaking.
• The role of ideas and knowledge in health and social/welfare policy.
• Policy capacity challenges.
• Non-knowledge, ignorance and misinformation in public policy.

Reader in International Relations, Director, Rotary Centre for International Studies in Peace and Conflict Resolution

Background:

Dr Hanson was a Stipendiary Lecturer in Politics at Magdalen College, Oxford University before she joined the University of Queensland in 1995. She has been a Visiting Scholar at the Liu Centre for the Study of Global Issues, Department of International Relations at the University of British Columbia, a Visiting Fellow at the Department of International Politics, University of Wales, Aberystwyth and a Visiting Scholar at Sciences Po in Paris.

Research Interests:

International security - especially from a critical security studies perspective, and focussing on the role of law, institutions and norms in shaping security policies; European security - the role of institutions such as NATO and the Organisation for Security and Cooperation in Europe (OSCE); Arms control and disarmament - particularly the debate on the elimination of nuclear weapons and the efforts to delegitimise the use or possession of weapons of mass destruction: human rights - both within Australia and at the global level, and with a strong focus on the creation of legal institutions (such as the International Criminal Court) designed to uphold human rights; humanitarian intervention - the theory and practice of humanitarian interventions and the implications of these for issues such as state sovereignty, human rights and global justice; normative International Relations theory and the role of ethics in world politics - the evolution of a series of norms and other constraints affecting world politics, and which includes an emphasis on concepts such as good international citizenship and human security. The 'English School' of thought in International Relations theory - the theoretical framework most closely associated with Hedley Bull, John Vincent and others focussing on the construction and operation of an 'international society'. Dr Hanson is currently working on a book titled 'Humanitarianism and nuclear weapons: building a global prohibition regime without the great powers' which examines the growth of norms and legal constraints on the possession and use of nuclear weapons.